Download
s00259-021-05557-z.pdf 1,38MB
WeightNameValue
1000 Titel
  • Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
1000 Autor/in
  1. Rogowski, Paul |
  2. Trapp, Christian |
  3. von Bestenbostel, Rieke |
  4. Eze, Chukwuka |
  5. Ganswindt, Ute |
  6. Li, Minglun |
  7. Unterrainer, Marcus |
  8. Zacherl, Mathias J. |
  9. Ilhan, Harun |
  10. Beyer, Leonie |
  11. Kretschmer, Alexander |
  12. Bartenstein, Peter |
  13. Stief, Christian |
  14. Belka, Claus |
  15. Schmidt-Hegemann, Nina-Sophie |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-10-10
1000 Erschienen in
1000 Quellenangabe
  • 49(4):1417-1428
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00259-021-05557-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921036/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Nodal recurrent prostate cancer (PCa) represents a common state of disease, amenable to local therapy. PSMA-PET/CT detects PCa recurrence at low PSA levels. The aim of this study was to evaluate the outcome of PSMA-PET/CT-based salvage radiotherapy (sRT) for lymph node (LN) recurrence.!##!Methods!#!A total of 100 consecutive patients treated with PSMA-PET/CT-based salvage elective nodal radiotherapy (sENRT) for LN recurrence were retrospectively examined. Patients underwent PSMA-PET/CT scan due to biochemical persistence (bcP, 76%) or biochemical recurrence (bcR, 24%) after radical prostatectomy (RP). Biochemical recurrence-free survival (BRFS) defined as PSA < post-RT nadir + 0.2 ng/ml and distant metastasis-free survival (DMFS) were calculated using the Kaplan-Meier method and uni- and multivariate analysis was performed.!##!Results!#!Median follow-up was 37 months. Median PSA at PSMA-PET/CT was 1.7 ng/ml (range 0.1-40.1) in patients with bcP and 1.4 ng/ml (range 0.3-5.1) in patients with bcR. PSMA-PET/CT detected 1, 2, and 3 or more LN metastases in 35%, 23%, and 42%, respectively. Eighty-three percent had only pelvic, 2% had only paraaortic, and 15% had pelvic and paraaortic LN metastases. Cumulatively, a total dose converted to EQD2!##!Conclusions!#!Overall, the present analysis shows that the so far, unmatched sensitivity and specificity of PSMA-PET/CT translates in comparably high BRFS and DMFS after PSMA-PET/CT-based sENRT for patients with PCa LN recurrence. Concomitant ADT, duration of ADT, PSA value before sRT, and localization of LN metastases were significant factors for improved outcome.
1000 Sacherschließung
lokal Oncology – Genitourinary
lokal Humans [MeSH]
lokal Salvage Therapy [MeSH]
lokal Prostate-Specific Antigen [MeSH]
lokal Positron Emission Tomography Computed Tomography [MeSH]
lokal Retrospective Studies [MeSH]
lokal Neoplasm Recurrence, Local/pathology [MeSH]
lokal Prostatic Neoplasms/diagnostic imaging [MeSH]
lokal Prostatic Neoplasms/radiotherapy [MeSH]
lokal Lymphatic Metastasis [MeSH]
lokal Original Article
lokal Gallium Radioisotopes [MeSH]
lokal Male [MeSH]
lokal Nodal radiotherapy
lokal Salvage radiotherapy
lokal Neoplasm Recurrence, Local/diagnostic imaging [MeSH]
lokal Androgen Antagonists [MeSH]
lokal ENRT
lokal PSMA PET/CT
lokal Prostatectomy [MeSH]
lokal Nodal recurrence
lokal Prostatic Neoplasms/surgery [MeSH]
lokal Prostate cancer
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-3351-8896|https://frl.publisso.de/adhoc/uri/VHJhcHAsIENocmlzdGlhbg==|https://frl.publisso.de/adhoc/uri/dm9uIEJlc3RlbmJvc3RlbCwgUmlla2U=|https://frl.publisso.de/adhoc/uri/RXplLCBDaHVrd3VrYQ==|https://frl.publisso.de/adhoc/uri/R2Fuc3dpbmR0LCBVdGU=|https://frl.publisso.de/adhoc/uri/TGksIE1pbmdsdW4=|https://frl.publisso.de/adhoc/uri/VW50ZXJyYWluZXIsIE1hcmN1cw==|https://frl.publisso.de/adhoc/uri/WmFjaGVybCwgTWF0aGlhcyBKLg==|https://frl.publisso.de/adhoc/uri/SWxoYW4sIEhhcnVu|https://frl.publisso.de/adhoc/uri/QmV5ZXIsIExlb25pZQ==|https://frl.publisso.de/adhoc/uri/S3JldHNjaG1lciwgQWxleGFuZGVy|https://frl.publisso.de/adhoc/uri/QmFydGVuc3RlaW4sIFBldGVy|https://frl.publisso.de/adhoc/uri/U3RpZWYsIENocmlzdGlhbg==|https://frl.publisso.de/adhoc/uri/QmVsa2EsIENsYXVz|https://frl.publisso.de/adhoc/uri/U2NobWlkdC1IZWdlbWFubiwgTmluYS1Tb3BoaWU=
1000 Hinweis
  • DeepGreen-ID: afa40cbdbd284ba9841ce32d9157973a ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451481.rdf
1000 Erstellt am 2023-05-11T13:40:48.435+0200
1000 Erstellt von 322
1000 beschreibt frl:6451481
1000 Zuletzt bearbeitet Tue Oct 24 08:04:08 CEST 2023
1000 Objekt bearb. Tue Oct 24 08:04:08 CEST 2023
1000 Vgl. frl:6451481
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451481 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source